Jenna Rannikko
jenna.h.rannikko@utu.fi |
- CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies (2025)
- Scientific Reports
- Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses (2025)
- OncoImmunology
- Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments (2024)
- Cancer Immunology Research
- Clinical landscape of macrophage-reprogramming cancer immunotherapies (2024)
- British Journal of Cancer
- Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment (2024)
- Journal for Immunotherapy of Cancer
- Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors : The phase I/II first-in-human MATINS trial (2023)
- Cell Reports Medicine
- The effect of acute exercise on circulating immune cells in newly diagnosed breast cancer patients (2023)
- Scientific Reports
- A distinct M2 macrophage infiltrate and transcriptomic profile decisively influence adipocyte differentiation in lipedema (2022)
- Frontiers in Immunology
- Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers (2022)
- Molecular Cancer Therapeutics
- Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial (2021)
- Clinical Cancer Research